Article
|
|
|
Services
|
|
|
Google Scholar
|
|
|
PubMed
|
|
|
|
BRIEF COMMUNICATION
Localization of Adrenocorticotropic Hormone-secreting Bronchial Carcinoid Tumor by Somatostatin-Receptor Scintigraphy
Mordechai Weiss;
Alon Yellin;
Monica Husza'r;
Zemach Eisenstein;
Jacob Bar-Ziv; and
Yodphat Krausz
1 August 1994 | Volume 121 Issue 3 | Pages 198-199
Most ectopic adrenocorticotropic hormone (ACTH)-secreting tumors are bronchial carcinoids [1], and many are malignant [2]. Intensive localization studies are therefore warranted. However, frequently, and especially in small centrally located tumors, various imaging modalities are inconclusive. Recently, somatostatin receptor scintigraphic studies using the radiolabeled long-acting somatostatin analog Indium-111-pentetreotide (Mallinckrodt Medical, Pettem, the Netherlands) have enabled the detection of medullary thyroid carcinoma and islet cell tumor, both secreting ACTH. However, a small ACTH-secreting bronchial carcinoid was not similarly identified [3]. We describe a patient with ACTH-producing malignant bronchial carcinoid in whom octreotide scintigraphy led to localization of the tumor and its successful resection.
A 22-year-old woman presented with a 3-month history of postpartum amenorrhea. Physical examination showed a blood pressure of 190/100 mm Hg, moon facies, and truncal obesity. Prominent purple striae covered her abdominal and chest walls. No goiter was palpable. Laboratory data included serum cortisol concentrations of 966 nmol/L at 0800 h (normal, 138 to 552 nmol/L) and 828 nmol/L at 2000 h (normal, 55 to 414 nmol/L). The plasma ACTH level at 0800 h was 60 pmol/L (normal, 2.3 to 13.8 pmol/L). Urinary free cortisol excretion was 1269 nmol/24 h (normal, 30 to 300 nmol/24 h). Dexamethasone administration of up to 16 mg daily in four equally divided doses did not significantly suppress serum cortisol and plasma ACTH levels or urinary free cortisol excretion. Cortisol and ACTH levels were both determined using commercially available kits (cortisol: DPC, Los Angeles, California; ACTH: Nichols Institute, San Juan Capistrano, California).
Contrast-enhanced pituitary computed tomographic (CT) scans were normal. Abdominal CT scans and magnetic resonance imaging studies showed that both adrenal glands were diffusely enlarged but that the pancreas seemed normal. An enhanced axial CT scan of the chest with 5-mm-thick slices showed no abnormality. Somatostatin receptor imaging done after intravenous administration of 20 µg of Indium-111-pentetreotide (222 MBq) showed a focus of increased activity in the left upper lobe, parahilar in location Figure 1 a, as early as 4 hours after the injection of the tracer. This focus was evident for at least an additional 20 hours thereafter. Repeat CT scanning of the chest with coronal reconstruction of the left upper lobe showed a central 1-cm rounded mass occluding a subsegmental bronchus of the apicoposterior segment of the left upper lobe. Distal to the mass, a wedge-shaped small zone of air trapping was noted Figure 1 b.
1. Doppman JL, Nieman L, Miller DL, Pass HI, Chang R, Cutler GB Jr, et al. Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients. Radiology. 1989; 172:115-24.
2. Leinung MC, Young WF Jr, Whitaker MD, Scheithauer BW, Trastek VF, Kvols LK. Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. Mayo Clin Proc. 1990; 65:1314-21.
3. Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol. 1993; 14:27-55.
4. van Noorden S, Varndell IA. Regulatory peptide immunocytochemistry at light- and electron microscopical levels. Experientia. 1987; 43:724-34.
5. Jex RK, van Heerden JA, Carpenter PC, Grant CS. Ectopic ACTH syndrome. Diagnostic and therapeutic aspects. Am J Surg. 1985; 149:276-82.
6. Findling JW. Eutopic or ectopic adrenocorticotropic hormone-dependent Cushing's syndrome? A diagnostic dilemma (Editorial). Mayo Clin Proc. 1990; 65:1377-80.
7. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988; 9:417-36.
8. Hearn PR, Reynolds CL, Johansen K, Woodhouse NJ. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-950 (sandostatin). Clin Endocrinol Oxf. 1988; 28:181-5.
9. Cheung NW, Boyages SC. Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours. Clin Endocrinol Oxf. 1992; 36:361-7.
10. Colombo P, Paganelli G, Magnani C, Fazio F, Faglia G. Scintigraphic studies with radiolabelled somatostatin analogue and anti-chromogranin A antibodies in patients with pituitary adenomas and ectopic Cushing's syndrome. J Endocrinol Invest 1993; 16(Suppl 1 to no. 8):S5.
11. Phlipponneau M, Nocaudie M, Epelbaum J, DeKeyzer Y, Lalau JD, Marchandise X, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab. 1994; 78:20-4.